Sodium Acetate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Sodium Acetate
- Sodium Acetate: From Electrolyte/Buffering Agent to Congenital Prothrombin Deficiency
Sodium Acetate: From Electrolyte/Buffering Agent to Congenital Prothrombin Deficiency
One-Sentence Summary
Sodium acetate is generically used as an electrolyte replenisher and alkalinising agent (e.g. in IV fluids, parenteral nutrition, and dialysate), though no formal SAHPRA-registered indication is on file for this evidence pack. The TxGNN model predicts it may be effective for Congenital Prothrombin Deficiency, but currently 0 clinical trials and 0 publications support this direction, and the model’s own mechanistic rationale states there is no known biological plausibility for this link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No registration on file; sodium acetate is generically used as an electrolyte/alkalinising agent (e.g. IV fluid additive, TPN component) |
| Predicted New Indication | Congenital Prothrombin Deficiency |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for sodium acetate is not available in this evidence pack. Based on general pharmacological knowledge, sodium acetate functions as a source of acetate ions and sodium, used to correct electrolyte imbalances and metabolic acidosis; it has no established role in coagulation factor synthesis or regulation.
Congenital prothrombin (Factor II) deficiency is a hereditary bleeding disorder caused by genetic defects affecting prothrombin production or function, typically managed with factor replacement or fresh frozen plasma. There is no overlap in pathophysiology between electrolyte/acid-base regulation and inherited coagulation factor synthesis.
The evidence pack’s own repurposing rationale explicitly states this candidate has no biological plausibility — the high TxGNN score likely reflects embedding similarity in the knowledge graph rather than a genuine pharmacological mechanism. This is a case where a high model score should not, on its own, be interpreted as clinical signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Sodium acetate has no SAHPRA registrations on record in this evidence pack (0 licenses, market status: Not marketed). No product/dosage-form information is available to summarise.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: PI warnings/contraindications data for this product could not be retrieved (flagged as a Blocking data gap), so a formal safety (S1) evaluation cannot proceed until this is resolved.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a very high TxGNN prediction score, there is no clinical trial or literature evidence, no known mechanistic pathway, and the model’s own rationale explicitly disclaims biological plausibility for sodium acetate in congenital prothrombin deficiency. This combination of a high score with zero supporting evidence and an implausible mechanism indicates the signal is not clinically actionable at this time.
To proceed, the following is needed:
- Mechanism of action (MOA) data for sodium acetate (currently a data gap)
- SAHPRA-approved Professional Information / label warnings and contraindications (currently a blocking data gap, required before any S1 safety evaluation)
- Preclinical or mechanistic studies establishing any link between acetate/electrolyte metabolism and Factor II synthesis, if this candidate is to be revisited
- Consideration of alternative candidates in this evidence pack with comparatively stronger (though still indirect) mechanistic support — e.g. dyspepsia and gastroparesis, where short-chain fatty acid (SCFA) physiology has documented effects on gastric emptying — as these reached decision stage S1 (“Research Question”) rather than S0 (“Hold”)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.